RecruitingPhase 1NCT07622368

A Study of IBI3031 in Participants With Thyroid Eye Disease

A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of IBI3031 in Participants With Thyroid Eye Disease

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.

Enrollment

66 participants

Start Date

Jun 30, 2026

Study Type

INTERVENTIONAL

Conditions

Thyroid Eye Disease

Summary

This is a multicenter, randomized, double-masked, placebo-controlled, single/multiple-dose-escalation trial conducted in Chinese participants with Thyroid Eye Disease (TED), aiming to evaluate the safety and tolerability of IBI3031 administered via subcutaneous or intravenous injection.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called IBI3031 and a drug called placebo for people with thyroid eye disease. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGIBI3031

subcutaneous injection or intravenous infusion.

DRUGplacebo

subcutaneous injection or intravenous infusion.

Locations(1)

the First Hospital of China Medical University

Shenyang, Liaoning, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07622368

Related Trials

A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease

NCT0640104444 locations

An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease

NCT074384056 locations

Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting

NCT050120331 location

Evaluating the Efficacy and Safety of Teprotumumab N01 in Patients With Thyroid Eye Disease.

NCT074230131 location

A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease

NCT0608897956 locations